Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02
() -- Armata Pharmaceuticals (ARMP) said Monday it has reached agreement with the US Food and Drug Administration on an agreed initial pediatric study plan for AP-SA02, clearing a regulatory requirement ahead of a potential biologics license application. The company said the plan covers the future evaluation of AP-SA02